ATG brings leading edge PepID technology to Netherlands vaccines symposium


ATG brings leading edge PepID technology to Netherlands vaccines symposium


ATG150x39

Press Release | ATG:biosynthetics GmbH

NOVEMBER 06, 2017

Merzhausen, Germany: – Advanced synthetic biology company ATG:biosynthetics (ATG) will present highlights of its innovative PepID peptide epitope tagging technology to the upcoming vaccine symposium in the Netherlands.

ATG will show how its strong PepID’s computational algorithms allow it to generate deterministic DNA-encoded peptide libraries that can then be expressed for antibody recognition, either by high-density microarrays, colony immunoblotting or using cell surface display. The new methodology aims to maximize the efficacy of multi-epitope vaccines and enables the development of innovative tools for previously unmet diagnostic needs.

Antimicrobial drug design

The symposium is largely organized by the MycoSynVac project, which aims to use cutting-edge synthetic biology methodologies to engineer Mycoplasma pneumoniae as a universal chassis for vaccination.

ATG:biosynthetics will be represented at the symposium by its CEO, Dr. Hubert S. Bernauer and its CSO, Dr. Josef Maier.

“The Vaccines Symposium provides an important opportunity to network with elite researchers in our field and show how PepID technology can provide an important route to developing more effective multi-epitope vaccines,” said Dr. Bernauer.

About ATG: biosynthetics

Advanced Technical Genetomics (ATG) is a German-based company that specializes in synthetic biology, combinatorial gene design and multi-gene expression. Located in Merzhausen near Freiburg, ATG offers a complete range of multi-gene and multi-peptide expression products and services for synthetic and molecular biology as well as allied research and development areas.

ATG: biosynthetics possesses particular strengths in designing tailor-made solutions (e.g., gene cluster and complete pathway designs) that harness its technologies and services in related product areas that include gene synthesis, bioinformatics, molecular in silico biodesign, epitope mapping and pathway engineering. These provide clients with individual products and services or integrated solutions that offer a complete product & service package for peptide/gene expression and synthetic biology applications.

ATG seeks partnerships and outsourcing projects that aim at developing and marketing high-potential applications, e.g. creating high efficiency DNA- and protein-based vaccines.

About Mycosyncvac vaccines symposium

The 2017 Vaccine Symposium jointly hosted by the MycoSynVac Consortium together with the Radboud University at Nijmegen, Netherlands, will bring scientists from different disciplines in academia and industry to share ideas on the impact of innovative vaccine formulation and delivery.

The one-day symposium will take place on November 15 at Radboud University Medical Center in Nijmegen, The Netherlands.

The symposium will involve up to 100 delegates and will feature keynote presentations from worldwide experts together with short talks of selected participants.

The event is organized by Barcelona-based MycoSynVac, with more information at: http://www.mycosynvac.eu/events/vaccine-symposium-vaccines-different-levels-complexity-subunit-whole-cell-formulations

Media Contacts

Dr. Hubert S. Bernauer , CEO, ATG:biosynthetics GmbH
Tel: +49 (0)761 888 9424
Email: info@atg-biosynthetics.de

Resources

Click on ATG at MycoSynVac Symposium for more information.
Click on ATG to contact the company directly.

a1


Supplier Information
Supplier: ATG:biosynthetics GmbH
Address: Weberstrasse 40, 79249 Merzhausen, Germany
Tel: +49 (0) 761 888 9424
Fax: +49 761 888 9425
Website: www.atg-biosynthetics.com/


Comments are closed.